Sign In
Buy FENC
$10.75
+0.260 (+2.48%)
At Close: Jul 13, 2026
Is the Options Market Predicting a Spike in Adherex Technologies Stock?
02:26pm, Monday, 06'th Jul 2026
Investors need to pay close attention to FENC stock based on the movements in the options market lately.
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
06:00am, Monday, 22'nd Jun 2026
RESEARCH TRIANGLE PARK, N.C., June 22, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today annou
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
06:00am, Monday, 15'th Jun 2026
RESEARCH TRIANGLE PARK, N.C., June 15, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today annou
Fennec Announces Results of Annual Meeting
04:30pm, Wednesday, 10'th Jun 2026
RESEARCH TRIANGLE PARK, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy
Adherex Technologies' PEDMARK Push Targets Larger AYA Market After Record Quarter
10:06am, Saturday, 23'rd May 2026
Fennec Pharmaceuticals NASDAQ: FENC executives outlined the company's commercial strategy for PEDMARK, its sodium thiosulfate product used to prevent cisplatin-related hearing loss, during a fireside
Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting
06:01pm, Thursday, 21'st May 2026
~ Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK ® (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations ~
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Monday, 18'th May 2026
RESEARCH TRIANGLE PARK, N.C., May 18, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announ
Fennec Pharmaceuticals Inc. (FENC) Q1 2026 Earnings Call Transcript
12:20pm, Thursday, 14'th May 2026
Fennec Pharmaceuticals Inc. (FENC) Q1 2026 Earnings Call Transcript
Adherex Technologies Q1 Earnings Call Highlights
11:07am, Thursday, 14'th May 2026
Adherex Technologies NASDAQ: FENC executives said Fennec Pharmaceuticals entered 2026 with stronger commercial momentum for PEDMARK, reporting higher first-quarter sales, positive operating cash flow
Adherex Technologies Inc. (FENC) Beats Q1 Earnings and Revenue Estimates
08:40am, Thursday, 14'th May 2026
Adherex Technologies Inc. (FENC) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to a loss of $0.04 per share a ye
Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
06:30am, Thursday, 14'th May 2026
~ Achieved First Quarter 2026 Total Net Revenues of $15.1 Million, Up 73% Year Over Year ~ ~ Field Sales Expansion Showing Early Signs of Positive Results with Record PEDMARK ® Demand in April 2026 ~
Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026
06:36am, Thursday, 07'th May 2026
RESEARCH TRIANGLE PARK, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Compa
FENC Secures Second Consecutive Inclusion in S&P Global Dow Jones Best in Class Emerging Markets Index
08:00am, Wednesday, 06'th May 2026
TAIPEI, May 6, 2026 /PRNewswire/ -- Far Eastern New Century Corporation ("FENC" or "the Company") has once again been selected as a constituent of S&P Global 2026 Dow Jones Best in Class (DJBIC) Emerg
Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center
07:03am, Tuesday, 07'th Apr 2026
~ University of Arizona Cancer Center Initiating Study to Explore Use of PEDMARK ® in AYA & Adult Patients with Solid Tumors Receiving Cisplatin ~
Adherex Technologies Inc. (NASDAQ:FENC) Receives Average Rating of “Moderate Buy” from Brokerages
04:42am, Wednesday, 01'st Apr 2026
Adherex Technologies Inc. (NASDAQ: FENC - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the six brokerages that are covering the company, Marketbeat Ratings repo
